Prof Heinz Ludwig speaks to ecancer about a randomised phase II study he presented at the virtual EHA 2020 meeting.
He explains that the trial is evaluating whether a carfilzomib-based regimen can overcome the negative impacts of high-risk cytogenetics in newly-diagnosed multiple myeloma (NDMM).
Prof Ludwig provides an update on the interim efficacy analysis of combined data of KRd (carfilzomib, lenalidomide, dexamethasone) versus KTd (carfilzomib, thalidomide, and dexamethasone) followed by maintenance with carfilzomib or control.
He also outlines the background, results and main conclusions of the study.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.